The molecular tumor board

被引:0
|
作者
Konukiewitz, Bjoern [1 ]
Kellers, Franziska [1 ]
Nettersheim, Alexander [1 ]
Pfarr, Nicole [2 ]
Kirfel, Jutta [3 ]
机构
[1] Univ klinikum Schleswig Holstein, Inst Pathol, Campus Kiel Arnold-Heller-Str 3, D-24105 Kiel, Germany
[2] Tech Univ Munich, TUM Sch Med & Hlth, Inst Pathol, Munich, Germany
[3] Univ klinikum Schleswig Holstein, Inst Pathol, Campus Lubeck, Lubeck, Germany
来源
ONKOLOGIE | 2024年 / 30卷 / 10期
关键词
Biomarker; Whole exome sequencing; Precision medicine; Targeted therapy; Molecular pathology; PATHOLOGY;
D O I
10.1007/s00761-024-01561-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Precision oncology is an integral part of patient care in the centers for personalized medicine of the German Network for Personalized Medicine at many university hospitals. The aim is to provide patients with advanced and rare tumor diseases, for whom classic guideline-conform treatment is no longer an option, access to molecular targeted therapy. To this end, a comprehensive molecular examination of the tumor tissue is carried out and a search is performed for genetic changes that can be targeted with medication. The molecular tumor board is the central body of precision oncology, in which experts from different disciplines discuss cases and recommend possible treatment options. The classic concept of tumor therapy is largely abandoned; the treatment recommendations are increasingly based on entity-agnostic approaches and off-label therapies that are strictly oriented towards the individual molecular profile of the tumor and for which a promising effect has been achieved in other tumor entities or case reports. Pathology plays a key role here, as the results of the molecular examinations are summarized in an integrative pathological-anatomical report and interpreted and evaluated in the context of the diagnosis.
引用
收藏
页码:916 / 921
页数:6
相关论文
共 50 条
  • [41] Developing the educational molecular tumor board in Ireland: Pilot to national initiative.
    Collins, Dearbhaile Catherine
    Poretti, Deirdre
    Murphy, Verena
    Ganter, Mathias
    Girotti, Romina
    Bird, Brian Healey
    Galibert, Marie-Dominique
    Dienstmann, Rodrigo
    McDermott, Raymond S.
    McVeigh, Terri Patricia
    Finn, Stephen P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board
    Gueguen, Lilia
    Olgiati, Louise
    Brutti-Mairesse, Clement
    Sans, Alric
    Le Texier, Vincent
    Verlingue, Loic
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [43] Molecular tumor board in uro-oncology-from a pathologist's view
    Gaisa, N. T.
    Kristiansen, G.
    Perner, S.
    UROLOGE, 2019, 58 (07): : 747 - 751
  • [44] Patients with colorectal and pancreatic cancer in the Molecular Tumor Board of a Center for Personalized Medicine
    Didion, Julia
    Jurkschat, Rika
    Perkhofer, Lukas
    Stilgenbauer, Stephan
    Gaidzik, Verena Ingeborg
    Ettrich, Thomas J.
    Kestler, Angelika
    Seufferlein, Thomas
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 149 - 149
  • [45] Clinical utility of a molecular tumor board (MTB) in a community oncology practice.
    Amatruda, Thomas
    Malisetti, Nithya
    Hirst, Jeff
    Vadnais, Malia
    Katipamula-Malisetti, Rajini
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] SNO pediatric molecular tumor board series: Successful beginnings and future directions
    Lindsay, Holly B.
    Erker, Craig
    Laughlin, Suzanne
    Huang, Annie
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [47] Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board
    Chu, L.
    Kelly, K.
    Gandara, D.
    Lara, P.
    Borowsky, A.
    Meyers, F.
    Mcpherson, J.
    Erlich, R.
    Almog, N.
    Schrock, A.
    Ali, S.
    Ross, J.
    Miller, V.
    Heilmann, A.
    Riess, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S986 - S986
  • [48] Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation
    Peh, Keng Hee
    Przybylski, Daniel J.
    Fallon, Michael J.
    Bergsbaken, Jason J.
    Hutson, Paul R.
    Yu, Menggang
    Deming, Dustin A.
    Burkard, Mark E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (05) : 1094 - 1102
  • [49] Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
    Klara Dorman
    Danmei Zhang
    Kathrin Heinrich
    Laurens Reeh
    Lena Weiss
    Michael Haas
    Georg Beyer
    Daniel Rössler
    Elisabetta Goni
    Bernhard W. Renz
    Jan G. D’Haese
    Wolfgang G. Kunz
    Max Seidensticker
    Stefanie Corradini
    Maximilian Niyazi
    Steffen Ormanns
    Jörg Kumbrink
    Andreas Jung
    Frederick Klauschen
    Jens Werner
    Julia Mayerle
    Michael von Bergwelt-Baildon
    Stefan Boeck
    Volker Heinemann
    C. Benedikt Westphalen
    Targeted Oncology, 2023, 18 : 257 - 267
  • [50] Molecular Tumor Board treatment predictions on rare EGFR exon 20 mutations
    van der Wekken, Anthonie J.
    Groves, Matthew R.
    ter Elst, Arja
    't Hart, Nils A.
    Hijmering-Kappelle, Lucie B.
    Hiltermann, Thijo J.
    van den Berg, Anke
    Timens, Wim
    Schuuring, Ed
    Groen, Harry J.
    CANCER RESEARCH, 2017, 77